By Gilang Cahya 
Cell division, the fundamental engine of life, can paradoxically become a harbinger of death when uncontrolled. This perilous transformation is at the heart of oncogenes, genes that normally regulate cellular growth but, when mutated, can unleash a relentless cascade of cancerous proliferation. A significant challenge in combating these rogue genes lies in their ability to evolve, becoming genetically independent from their origin and thus evading therapeutic interventions aimed at their source. This genetic autonomy has historically made it exceedingly difficult for scientists to effectively shut down cancer cell replication at its inception.
However, a groundbreaking discovery by researchers at Rockefeller University offers a potent new weapon against such recalcitrant malignancies. In a study published in the prestigious journal Molecular Therapy, the team has successfully employed small interfering RNAs (siRNAs) to target and silence a specific oncogene responsible for fibrolamellar hepatocellular carcinoma (FLC), a rare and often aggressive form of liver cancer. This innovative approach harnesses an innate cellular mechanism for gene silencing, demonstrating a significant leap forward in the fight against this devastating disease.
Silencing the Rogue Gene: A Targeted Approach
The research focused on the DNAJB1::PRKACA fusion oncogene, the genetic anomaly driving FLC. This aberrant gene arises from the unnatural fusion of two genes located on chromosome 19: DNAJB1, which typically produces heat-shock proteins vital for maintaining cellular stability, and PRKACA, which encodes kinase A, an enzyme crucial for cellular metabolic functions. The resulting fusion gene creates a dysfunctional hybrid protein that promotes FLC formation, though the precise molecular mechanisms remain an active area of investigation.
Christoph Neumayer, a Ph.D. student in Rockefeller’s Laboratory of Cellular Biophysics, led the study. His team successfully delivered siRNAs into FLC cells by leveraging a specific surface receptor, ASGR1, which is predominantly expressed on liver cells. This receptor acts as a cellular "doorway," allowing the siRNAs to enter and effectively block the fusion oncogene from producing the illness-inducing proteins that fuel tumor growth. This marks the first time siRNAs have been utilized to impede the progression of FLC.
"This is proof of concept that siRNAs can be used for FLC, as well as adult liver cancers, which are much more common, and other tumor types elsewhere in the body," Neumayer stated, underscoring the broader implications of their findings. The ability to precisely target and silence a specific oncogene without widespread collateral damage to healthy cells represents a significant advancement in precision medicine.
A Decade of Discovery and a Legacy of Hope
The journey leading to this breakthrough is deeply personal and spans over a decade. The DNAJB1::PRKACA fusion oncogene was initially identified by researchers in Sanford M. Simon’s lab in 2014. This discovery followed the diagnosis of liver disease in Simon’s daughter, Elana, who was then a teenager. After undergoing surgical removal of the resulting tumor—the sole treatment option for FLC at the time—Elana collaborated with her father on research aimed at uncovering the cause of her illness. Their pivotal findings were published in the esteemed journal Science.
Since this initial discovery, Simon’s lab has been dedicated to unraveling the complex mechanisms underlying FLC and developing effective therapeutic strategies. The current siRNA research is part of a comprehensive, multi-pronged approach. This strategy also includes repurposing existing drugs for FLC treatment and developing novel molecules known as PROTACs (Proteolysis Targeting Chimeras) designed to selectively degrade the DNAJB1::PRKACA protein. The drug repurposing initiative is in advanced stages of preparation for clinical trials, and research involving PROTACs is a component of an international collaboration that recently received a substantial $25 million Cancer Grand Challenges grant. This grant will fuel efforts to develop treatments for high-risk, oncogene-driven cancers, particularly in pediatric patients.
Overcoming the Cellular Barrier: The GalNAc Conjugate Advantage
A primary obstacle in delivering siRNA-based therapies is their inability to readily cross cell membranes. The researchers meticulously designed siRNAs to specifically target the unique RNA sequence of the fusion oncogene. However, the challenge remained in efficiently transporting these therapeutic molecules into the FLC cells.
Fortunately, a natural solution presented itself through the ASGR1 receptor. This receptor, found on liver cells, functions in conjunction with a binding molecule called GalNAc as a highly efficient "waste disposal team" for the liver. The research team recognized the potential of this cellular mechanism. GalNAc conjugate therapies, which link siRNA molecules to the GalNAc ligand, are already a validated therapeutic strategy for conditions such as hereditary transthyretin-mediated amyloidosis and atherosclerotic cardiovascular disease. This established precedent provided a strong foundation for their experimental approach.
By attaching their custom-designed siRNA to the GalNAc ligand, the Rockefeller team created a conjugate therapy capable of binding to the ASGR1 receptor and facilitating the entry of the therapeutic payload into the FLC cells. This ingenious strategy bypasses the inherent limitations of siRNA delivery, opening a direct pathway to the target oncogene.
Promising Results in Preclinical Models
The efficacy of this GalNAc-conjugated siRNA therapy was rigorously tested in a series of preclinical models, including various mouse tumor models and human cell cultures. The results were highly encouraging. The therapy was successfully delivered into the target cells across all tested contexts. Crucially, it led to a significant reduction in the mRNA produced by the oncogene, thereby preventing the synthesis of the disease-driving protein. This intervention effectively halted tumor progression, causing FLC tumors to stagnate or even shrink.
A significant aspect of the findings was the absence of detectable liver toxicity in the mouse models, indicating that the siRNAs were well-tolerated by the animals. This is a critical factor for any therapeutic intervention, especially those targeting the liver.
Neumayer acknowledged that the current results demonstrated tumor inhibition rather than complete eradication, stating, "What we saw was tumor inhibition, when we had hoped to outright kill the tumor. Our future direction will be to try to figure out how to improve that." This forward-looking perspective highlights the ongoing commitment to refining the therapy for maximum clinical impact.
Unprecedented Specificity: A Targeted Blow to Cancer
A key concern with any cancer therapy is its specificity and potential for off-target effects. To address this, the researchers conducted crucial experiments to assess the siRNA’s precision. They injected the conjugate therapy into tumor cells of a different type of liver cancer, distinct from FLC. The results confirmed the high degree of specificity; the siRNA had no toxic impact on these other cancer cells.
"We wanted to show that our siRNA is so targeted to the FLC fusion oncogene that it has no side effects on other cells—even on other cancer cells," Neumayer emphasized. This targeted action is paramount in minimizing the debilitating side effects often associated with conventional cancer treatments, improving patient quality of life and treatment adherence.
The implications of this targeted approach extend far beyond FLC. The success in achieving such high specificity suggests that siRNA-based therapies hold immense potential for treating a wide range of tumors throughout the body. As genetic therapies continue to evolve, siRNA medicines are poised to become a transformative class of therapeutics, offering new hope for patients with previously intractable cancers.
Broader Implications and Future Directions
The discovery by the Rockefeller University team represents a significant milestone in the ongoing battle against cancer. The ability to precisely target and silence specific oncogenes, particularly those that have historically resisted therapeutic intervention, opens new avenues for treatment development.
Supporting Data and Context:
Fibrolamellar hepatocellular carcinoma (FLC) is an extremely rare liver cancer, accounting for less than 1% of all primary liver cancers. It typically affects adolescents and young adults, with a median age of diagnosis around 15 years. The fusion oncogene DNAJB1::PRKACA is found in nearly all FLC cases, highlighting its central role in the disease’s pathogenesis. Despite its rarity, FLC is known for its aggressive nature and poor prognosis, with limited treatment options beyond surgical resection, which is not always feasible. The average 5-year survival rate for FLC is often cited as being below 50%. The development of targeted therapies like the siRNA strategy is therefore critically needed.
Timeline of Key Developments:
- 2014: Discovery of the DNAJB1::PRKACA fusion oncogene as the driver of FLC by researchers in Sanford M. Simon’s lab.
- Ongoing: Sanford M. Simon’s lab continues research into FLC mechanisms and therapeutic development, including drug repurposing and PROTAC development.
- Recent: Successful demonstration of siRNAs, delivered via GalNAc conjugation, to inhibit FLC tumor growth in preclinical models.
- Current: siRNA research published in Molecular Therapy, marking the first use of siRNAs against FLC.
- Future: Clinical trial preparations for drug repurposing; further optimization of siRNA therapy for tumor eradication; ongoing PROTAC research as part of a major international grant.
Broader Impact and Implications:
The success of this siRNA strategy has far-reaching implications for cancer therapy:
- Precision Oncology: It exemplifies the power of precision medicine, where therapies are tailored to the specific genetic underpinnings of a patient’s cancer. This reduces the likelihood of side effects and increases treatment efficacy.
- Targeting "Undruggable" Targets: Oncogenes, particularly fusion oncogenes, can be difficult to target with traditional small molecule drugs. siRNA technology offers a novel way to silence these targets by interfering with their genetic instructions.
- Therapeutic Modality for Rare Cancers: For rare cancers like FLC, where established treatment protocols are limited, such breakthroughs offer a glimmer of hope and pave the way for developing effective therapies.
- Platform for Other Cancers: The success in liver cells using the ASGR1 receptor and GalNAc conjugation could serve as a blueprint for developing similar targeted siRNA therapies for other cancers, provided appropriate cell-specific receptors can be identified.
- Advancement in Genetic Therapies: This research contributes to the growing field of genetic therapies, showcasing their potential to revolutionize medicine by directly addressing the root cause of diseases at the genetic level.
The ongoing research by Simon’s lab, supported by substantial grants and collaborations, underscores a robust commitment to translating these scientific discoveries into tangible clinical benefits. The development of effective treatments for oncogene-driven cancers remains a paramount goal, and the recent findings offer a compelling testament to the progress being made in this critical area of medical research. The scientific community will be keenly watching as this innovative siRNA approach moves closer to clinical application, potentially transforming the outlook for patients with FLC and other challenging cancers.
